KYLA INGRAM: Open Payments
NPI 1427697069 · ANKENY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,574 in 70 payments from 19 companies in 2025. Trend: 2023 $695 · 2024 $708 · 2025 $1,574
Food & beverage: $1,406Education: $168
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $280 |
| Grifols USA, LLC | 6 | $233 |
| GENZYME CORPORATION | 16 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $141 |
| PFIZER INC. | 5 | $136 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Amgen Inc. | 2 | $68 |
| Novartis Pharmaceuticals Corporation | 3 | $59 |
| Lilly USA, LLC | 2 | $57 |
| CSL Behring | 2 | $54 |
Products named: DUPIXENT, Xembify, OCTAGAM IMMUNE GLOBULIN (HUMAN), AIRSUPRA, TEZSPIRE, CUVITRU, TALTZ, Hizentra.
Industry payments across IA — which companies pay providers there.
